会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    • MRNA联合治疗癌症的研究
    • WO2017201352A1
    • 2017-11-23
    • PCT/US2017/033425
    • 2017-05-18
    • MODERNATX, INC.
    • FREDERICK, JoshuaHEWITT, SusannahBAI, AilinHOGE, StephenPRESNYAK, VladimirMCFADYEN, IainBENENATO, KerryKUMARASINGHE, Ellalahewage Sathyajith
    • A61K39/395C12N15/11C07K14/54C07K14/705
    • The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.
    • 本公开涉及核酸(例如,mRNA)组合疗法在治疗癌症中的用途。 本公开内容提供了用于其制备,制造和治疗用途的组合物和方法,其中所述组合物包含至少两种多核苷酸(例如mRNA),其中所述至少两种多核苷酸选自(i)多核苷酸 编码免疫应答引物(例如IL23),(ii)编码免疫应答共刺激信号(例如OX40L)的多核苷酸,(iii)编码检查点抑制剂(例如抗CTLA-4抗体)的多核苷酸, 和(iv)其组合。 本文公开的治疗方法包括例如在有此需要的受试者中施用本文公开的用于治疗癌症的组合疗法,例如通过减小肿瘤的大小或抑制肿瘤的生长。 在一些方面,本文公开的组合疗法在肿瘤内施用。